ReNeuron has high hopes of being the first to reach the US market with a novel stem cell therapy for use in patients with disabilities caused by stroke – CEO Olav Hellebø outlines the company's plans for Phase III and eventual commercialization.
ReNeuron Group PLC is planning "world domination" for stem cell therapy use in ischemic stroke, says CEO Olav Hellebø; the UK biotech wants to commercialize its potential blockbuster therapy alone in the US and Europe, but seek a local partner to help conquer the market in Japan.
ReNeuron's lead compound, CTX (ReN001), is being developed as a cell therapy treatment to reverse the functional deficits associated with...
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
